UiPath Announces Third Quarter Fiscal 2026 Financial Results Conference Call

UiPath, Inc. (NYSE: PATH), a global leader in agentic automation , today announced it will report financial results for its third quarter fiscal 2026 ended October 31, 2025 after the market closes on Wednesday, December 3, 2025. Management will host a conference call and webcast to discuss the Company's financial results at 5:00 pm ET.

UiPath Third Quarter Fiscal 2026 Financial Results Conference Call
When: Wednesday, December 3, 2025
Time: 5:00 pm ET
Conference ID: 13756820
Live Call: 1-877-407-8309 (US/Canada Toll-Free) or 1-201-689-8057 (Toll)
Replay: A webcast replay of the conference call will be available on the investor relations website for one year.
Webcast: https://ir.uipath.com

About UiPath

UiPath (NYSE: PATH) is a global leader in agentic automation, empowering enterprises to harness the full potential of AI agents to autonomously execute and optimize complex business processes. The UiPath Platformâ„¢ uniquely combines controlled agency, developer flexibility, and seamless integration to help organizations scale agentic automation safely and confidently. Committed to security, governance, and interoperability, UiPath supports enterprises as they transition into a future where automation delivers on the full potential of AI to transform industries.

Investor Relations Contact
Allise Furlani
Investor.relations@uipath.com
UiPath

Media Contact
PR@uipath.com
UiPath

News Provided by Business Wire via QuoteMedia

PATH
The Conversation (0)
Numinus Wellness Provides Corporate Update

Numinus Wellness Provides Corporate Update

Numinus Wellness Inc. (TSX: NUMI) (OTCQX: NUMIF) ("Numinus" or the "Company"), a mental health care company focused on innovative behavioral health treatments with a focus on safe, evidence-based psychedelic-assisted therapies, is providing a corporate update.Change of auditorsOn October 10,... Keep Reading...
New Data from the Phase II ARCHER Trial Demonstrate CardiolRx Improves Heart Structure in Patients with Acute Myocarditis, Supporting Expansion Across Inflammatory Cardiac Conditions

New Data from the Phase II ARCHER Trial Demonstrate CardiolRx Improves Heart Structure in Patients with Acute Myocarditis, Supporting Expansion Across Inflammatory Cardiac Conditions

Phase II ARCHER trial showed a significant reduction in left ventricular (LV) mass (p=0.0117) and improvements in multiple key cardiac MRI (CMR) measures of structural heart recovery in patients with acute myocarditis.Results provide clinical evidence that CardiolRxâ„¢ reduces inflammation-driven... Keep Reading...
Altech Batteries Ltd  Board Renewal and Strategic Focus

Altech Batteries Ltd Board Renewal and Strategic Focus

Perth, Australia (ABN Newswire) - Altech Batteries Limited (ASX:ATC,OTC:ALTHF) (FRA:A3Y) (OTCMKTS:ALTHF) advised that its newly constituted Board has commenced a comprehensive strategic reset to position the Company for successful commercialisation of its core battery technologies. The refreshed... Keep Reading...
Locksley Resources Limited  Drill Program Operations Commence at El Campo

Locksley Resources Limited Drill Program Operations Commence at El Campo

Perth, Australia (ABN Newswire) - Locksley Resources Limited (ASX:LKY,OTC:LKYRF) (FRA:X5L) (OTCMKTS:LKYRF) provided a significant operational update for its Mojave Project in California, confirming that the project has now transitioned into the drilling program phase. HIGHLIGHTS - Activities... Keep Reading...

Latest Press Releases

Related News